First AD

Second AD

Advances in Anti-HER2 ADCs in Patients With Advanced or Recurrent Endometrial Cancer

Gynecologic Oncology

CLO-22-OSD1210 - /clinical/gynecologic-oncology

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Recent Advances in Treating Endometrial and Cervical Cancers

Peer Exchange

Key opinion leaders share excitement about antibody-drug conjugates targeting HER2 in advanced or recurrent endometrial cancer, and debate optimal HER2 testing methods, with some preferring gastric cancer scoring criteria over breast cancer criteria.

Diagnosing and Staging Patients With Endometrial Cancer

Updated NCCN Guidelines for the Treatment of Advanced or Recurrent Endometrial Cancer

Shared Decision-Making in Advanced or Recurrent Endometrial Cancer 

The Role of dMMR in the Progression of Endometrial Cancer

Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial

The NRG-GY018 Trial: Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer

Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer

Recent Data on Anti-TROP2 ADCs for Patients With Advanced or Recurrent Endometrial Cancer

Future Directions in the Treatment of Advanced or Recurrent Endometrial Cancer

Staging and Biomarker Testing For Patients With Cervical Cancer

Recent Updates in NCCN Guidelines for the Treatment of Recurrent or Metastatic Cervical Cancer

Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer

Ocular Toxicity Management Strategies for Patients With Cervical Cancer Receiving ADCs

Clinical Trials Evaluating Tisotumab Vedotin in Patients with Recurrent or Metastatic Cervical Cancer

Emerging Data on Anti-HER2 ADCs in Patients With Cervical Cancer

Future Directions in the Treatment of Recurrent or Metastatic Cervical Cancer